Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration | Zendy

Raffaella Rosso | Zendy; Antonio Di Biagio | Zendy; Chiara Dentone | Zendy; Guido Castelli Gattinara | Zendy; Alessandra M. Martino | Zendy; M Viganò | Zendy; Marzia Merlo | Zendy; Carlo Giaquinto | Zendy; Osvalda Rampon | Zendy; Matteo Bassetti | Zendy; Giorgio Gatti | Zendy; Claudio Viscoli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration

Author(s) -

Raffaella Rosso,

Antonio Di Biagio,

Chiara Dentone,

Guido Castelli Gattinara,

Alessandra M. Martino,

M Viganò,

Marzia Merlo,

Carlo Giaquinto,

Osvalda Rampon,

Matteo Bassetti,

Giorgio Gatti,

Claudio Viscoli

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl136

Subject(s) - cmin , lopinavir , regimen , ritonavir , medicine , lopinavir/ritonavir , cmax , interquartile range , dose , pharmacology , pharmacokinetics , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy

Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m(2) twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research